Lung Cancer: 2017 New DirectionsJonathan Goldman, MD
About the Lecture
More than 200,000 people are diagnosed with lung cancer every year in this country. Only recently have we understood that there are distinct subtypes of lung cancer. Most importantly, this has allowed us to develop the most appropriate treatment for each type. In many cases, these are well-tolerated and highly effective pills. Nevertheless, there is still much work to be done, as we try to improve the therapies we do have and to investigate new directions for treatment. For example, in the past few years, immune therapies were shown to tap into the body’s own defense systems to attack the cancer. Clinical trials have led us to these exciting and novel treatments, and can be an important consideration in the care of all patients.
Jonathan Goldman, MD is the Director of Clinical Trials in Thoracic Oncology and the Associate Director of Drug Development. His research is focused on cancer drug development and on treatment for lung cancers. He develops novel anti-cancer drugs that have been identified in the lab and investigates their toxicity and efficacy for patients in the clinic.
7:00 p.m. – 9:00 p.m.
6:45 – 7:00: Arrival & Refreshments
7:00 – 7:15: Anne Coscarelli, Ph.D, Introduction to Center
7:15 – 7:20: Anne Coscarelli, Ph.D., Speaker Introduction
7:20 – 8:55: Speaker Presentation, Q&A
8:55 – 9:00: Closing
Ronald Reagan UCLA Medical Center (RRMC) Auditorium,
B Level, Room B130, 757 Westwood Plaza, Los Angeles, CA 90095
Attendance is Free.
Available at the Medical Plaza or Ronald Reagan Medical Center lots for $12.00